Skip to main content

Tekturna HCT FDA Approval History

FDA Approved: Yes (First approved January 18, 2008)
Brand name: Tekturna HCT
Generic name: aliskiren and hydrochlorothiazide
Dosage form: Tablets
Company: Novartis Pharmaceuticals Corporation
Treatment for: High Blood Pressure

Tekturna HCT (aliskiren and hydrochlorothiazide) is a single-tablet combination therapy for the treatment of high blood pressure.

Development timeline for Tekturna HCT

DateArticle
Jul 21, 2009Approval FDA Approves Tekturna HCT as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Jan 22, 2008Approval Tekturna HCT, a Single-Tablet Combination of Tekturna and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
May 21, 2007Single-Tablet Combination of Tekturna and Diuretic, an Important New Option for People With High Blood Pressure, Accepted for Review in U.S.

See also

Tekturna HCT (aliskiren and hydrochlorothiazide) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer